IRS1 and neoplasm: The increased expression of ciRS-7 in tumor tissues leads to inhibition of miR-7 and subsequent activation of several oncogenes, including epidermal growth factor receptor (EGFR), rapidly accelerated fibrosarcoma 1 (RAF1), phosphoinositide 3-kinase catalytic subunit delta (PIK3CD), mammalian target of rapamycin (mTOR), and insulin receptor substrate-1 (IRS-1) [13,14,15].